<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dupilumab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dupilumab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dupilumab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="112588" href="/d/html/112588.html" rel="external">see "Dupilumab: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="120255" href="/d/html/120255.html" rel="external">see "Dupilumab: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F49955736"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Dupixent</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52872260"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Dupixent</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F49748343"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Interleukin-4 Receptor Antagonist;</li>
<li>
                        Monoclonal Antibody;</li>
<li>
                        Monoclonal Antibody, Anti-Asthmatic</li></ul></div>
<div class="block doa drugH1Div" id="F49955105"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="00b8df97-45d1-4ddd-8990-31e176ed3832">Asthma, moderate to severe eosinophilic or oral glucocorticoid dependent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, moderate to severe eosinophilic or oral glucocorticoid dependent:</b>
<b>Note:</b> May consider as add-on therapy in patients with moderate to severe eosinophilic asthma (peripheral blood eosinophils ≥150 cells/mcL) or patients who are inadequately controlled on standard therapies (eg, an inhaled glucocorticoid with a long-acting beta agonist and/or oral glucocorticoids). The eosinophil threshold required for patients on systemic glucocorticoids is less clear. A minimum of 4 months of treatment is suggested to determine efficacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> 400 mg once (given as two 200 mg injections), followed by 200 mg every other week.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>OR</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> 600 mg once (given as two 300 mg injections), followed by 300 mg every other week. <b>Note:</b> Preferred dosing for patients with severe asthma (eg, oral glucocorticoid dependent).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="93db2a31-f0e4-40e5-a63e-d8fbd25ae6f5">Asthma with comorbid moderate to severe atopic dermatitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma with comorbid moderate to severe atopic dermatitis:</b>
<b>SUBQ: </b>600 mg once (given as two 300 mg injections), followed by 300 mg every other week.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c67e9e2b-6dad-418d-9ecc-84f4de0f5978">Atopic dermatitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atopic dermatitis: SUBQ:</b> 600 mg once (given as two 300 mg injections), followed by 300 mg once every other week.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="22b74007-b78d-455f-83e5-e24470b792c9">Chronic obstructive pulmonary disease, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease, refractory (prevention of exacerbations) (off-label use): Note:</b> May consider as add-on therapy in patients with refractory eosinophilic chronic obstructive pulmonary disease (peripheral blood eosinophils ≥300 cells/mcL) who are inadequately controlled on standard therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37272521']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37272521'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> 300 mg once every other week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37272521']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37272521'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c7eb41f5-ab77-43d2-b32d-436b6b436e7f">Eosinophilic esophagitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Eosinophilic esophagitis: SUBQ:</b> 300 mg once weekly.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="07c04359-f558-4413-b1f9-07785c945f35">Prurigo nodularis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prurigo nodularis: SUBQ: </b>600 mg once (given as two 300 mg injections), followed by 300 mg once every other week.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1d7e23b1-474f-453b-9277-32d4d2a253f3">Rhinosinusitis with nasal polyposis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis (chronic) with nasal polyposis:</b>
<b>SUBQ:</b> 300 mg once every other week.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Missed doses:</b> If a weekly dose is missed, administer the dose as soon as possible, and start a new weekly schedule from the date of the last administered dose. If an every-other-week dose is missed, administer within 7 days from the missed dose and then resume the original schedule. If the missed dose is not administered within 7 days, wait until the next dose on the original schedule.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991763"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50989020"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F49955106"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F52076682"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="120255" href="/d/html/120255.html" rel="external">see "Dupilumab: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Patients should be current with all age-appropriate immunizations prior to initiation.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6eaf0529-96af-46d7-a15e-d8e3d1ed0ca2">Asthma, maintenance therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma (moderate to severe), maintenance therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to &lt;12 years: Prefilled pen, prefilled syringe:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> In children 6 to &lt;12 years, an initial loading dose is not necessary. If patient has atopic dermatitis comorbidity, the dosing for atopic dermatitis (including the initial loading dose) should be used to determine dupilumab therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">15 to &lt;30 kg: SUBQ: 100 mg every other week <b>or</b> 300 mg <b>every 4 weeks</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">≥30 kg: SUBQ: 200 mg every other week.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Prefilled pen, prefilled syringe: SUBQ: Initial: 400 mg once (administered as two 200 mg injections), followed by a maintenance dose of 200 mg every other week <b>or </b>600 mg once (administered as two 300 mg injections), followed by a maintenance dose of 300 mg every other week.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Corticosteroid-dependent asthma or comorbid moderate to severe atopic dermatitis: </i>Prefilled pen, prefilled syringe: SUBQ: Initial: 600 mg once (administered as two 300 mg injections), followed by a maintenance dose of 300 mg every other week.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d8ecd230-ce3b-46da-85b5-ab9bafc77949">Atopic dermatitis, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atopic dermatitis (AD), moderate to severe: Note:</b> May be used in combination with topical corticosteroids or topical calcineurin inhibitors.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children &lt;6 years: <b>Note:</b> Prefilled syringe may be used in ages ≥6 months; prefilled pen is only for use in ages ≥2 years. An initial loading dose is not necessary in pediatric patients &lt;6 years.</p>
<p style="text-indent:-2em;margin-left:6em;">5 to &lt;15 kg: SUBQ: 200 mg <b>every 4 weeks</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">15 to &lt;30 kg: SUBQ: 300 mg <b>every 4 weeks</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents ≤17 years: Prefilled pen, prefilled syringe:</p>
<p style="text-indent:-2em;margin-left:6em;">15 to &lt;30 kg: SUBQ: Initial: 600 mg once (administered as two 300 mg injections), followed by a maintenance dose of 300 mg <b>every 4 weeks</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">30 to &lt;60 kg: SUBQ: Initial: 400 mg once (administered as two 200 mg injections), followed by a maintenance dose of 200 mg every other week.</p>
<p style="text-indent:-2em;margin-left:6em;">≥60 kg: SUBQ: Initial: 600 mg once (administered as two 300 mg injections), followed by a maintenance dose of 300 mg every other week.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: Prefilled pen, prefilled syringe: SUBQ: Initial: 600 mg once (administered as two 300 mg injections), followed by a maintenance dose of 300 mg every other week.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c7eb41f5-ab77-43d2-b32d-436b6b436e7f">Eosinophilic esophagitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Eosinophilic esophagitis:</b> Children ≥12 years and Adolescents, weighing ≥40 kg: Prefilled pen, prefilled syringe: SUBQ: 300 mg once weekly.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52605662"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F52605663"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F56631439"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Dermatologic reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urticaria </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31994421']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31994421'])">Ref</a></span>), <b>angioedema</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33099796']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33099796'])">Ref</a></span>), <b>skin rash</b>, <b>erythema nodosum </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34917722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34917722'])">Ref</a></span>), <b>erythema multiforme</b>, and <b>serum sickness-like reaction</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32594596']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32594596'])">Ref</a></span>) have been reported. Other reactions include <b>alopecia</b> (areata) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31789276']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31789276'])">Ref</a></span>), <b>psoriasis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34175141','lexi-content-ref-32665517','lexi-content-ref-32178985','lexi-content-ref-34310097']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34175141','lexi-content-ref-32665517','lexi-content-ref-32178985','lexi-content-ref-34310097'])">Ref</a></span>), <b>facial erythema</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32822798','lexi-content-ref-33428978','lexi-content-ref-32622143','lexi-content-ref-31228530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32822798','lexi-content-ref-33428978','lexi-content-ref-32622143','lexi-content-ref-31228530'])">Ref</a></span>), and <b>immune thrombocytopenia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33349889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33349889'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Immediate hypersensitivity reactions (urticaria/angioedema): Non-dose-related; likely immunologic (ie, IgE-mediated, with specific antibodies formed against a drug allergen following initial exposure) or due to histamine-releasing activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30275849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30275849'])">Ref</a></span>). Serum sickness-like reaction: Has been associated with high titers of antibodies to dupilumab. Alopecia areata, psoriasis: Unknown; alteration of immune signalling may upregulate T-helper type 1 (Th1) and Th17 pathways (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30530389','lexi-content-ref-34175141']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30530389','lexi-content-ref-34175141'])">Ref</a></span>). Facial erythema: Unknown; proposed theories include hypersensitivity reaction, paradoxical flaring of allergic contact dermatitis, and seborrheic dermatitis-like reaction to facial <i>Malassezia</i> species (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31228530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31228530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; immediate hypersensitivity reactions; generally occur within 1 hour of administration, but have been reported 1 month after dupilumab injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-33099796']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-33099796'])">Ref</a></span>). Delayed; serum sickness-like reaction occurred 10 days after first injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32594596']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32594596'])">Ref</a></span>). Facial or neck erythema occurred an average of 11 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33428978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33428978'])">Ref</a></span>). Varied; alopecia areata has occurred 48 hours after the first injection up to 28 months of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34175141']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34175141'])">Ref</a></span>). Psoriasis has occurred 1 month to 18 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34175141']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34175141'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ocular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ocular surface disorders, including <b>conjunctivitis</b>, <b>blepharitis</b>,<b> keratitis</b>, <b>eye pruritus</b>, and <b>dry eye syndrome</b> have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30851191','lexi-content-ref-33481203','lexi-content-ref-32826648','lexi-content-ref-32822798','lexi-content-ref-33038471','lexi-content-ref-33725800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30851191','lexi-content-ref-33481203','lexi-content-ref-32826648','lexi-content-ref-32822798','lexi-content-ref-33038471','lexi-content-ref-33725800'])">Ref</a></span>). Although most cases are mild to moderate with resolution occurring in 80% of cases despite continued treatment with dupilumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30851191']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30851191'])">Ref</a></span>), cases of severe cicatrizing <b>blepharoconjunctivitis</b> have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34114910']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34114910'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; one possible mechanism includes reduction in ocular cytokines provides environment for <i>Demodex</i> mites to grow, resulting in IL-17-mediated inflammation, eosinophilia, and systemic IL-13 inhibition indirectly leading to reduction in conjunctival goblet cells and mucin production, contributing to tear film insufficiencies and subsequent corneal erosions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31728936','lexi-content-ref-35814891']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31728936','lexi-content-ref-35814891'])">Ref</a></span>). Other possible mechanisms include unmasking of preexistent subclinical atopic or allergic inflammatory processes, increased expression of proinflammatory molecules (ie, OX40L), and a local immunodeficiency resulting in local bacterial and viral infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35814891']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35814891'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; 2 weeks to ~4 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31728936','lexi-content-ref-35814891']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31728936','lexi-content-ref-35814891'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Severe atopic dermatitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31728936','lexi-content-ref-30851191','lexi-content-ref-33481203','lexi-content-ref-31554632','lexi-content-ref-30167653']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31728936','lexi-content-ref-30851191','lexi-content-ref-33481203','lexi-content-ref-31554632','lexi-content-ref-30167653'])">Ref</a></span>). No increase in incidence of conjunctivitis in dupilumab-treated asthma, chronic rhinosinusitis with nasal polyps, or eosinophilic esophagitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31728936','lexi-content-ref-34495603']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31728936','lexi-content-ref-34495603'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Previous history of allergic conjunctivitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30851191','lexi-content-ref-32956738']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30851191','lexi-content-ref-32956738'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F49762738"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adolescents or adults unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (1% to 16%; neutralizing: 2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (6% to 38%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (3%), gastritis (2%), toothache (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Helminthiasis (children: 2%; including ascariasis and enterobiasis), herpes virus infection (≤4%; including herpes simplex infection, herpes zoster infection [including ophthalmic herpes zoster], and oral herpes simplex infection)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (3%), insomnia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (2% to 3%), myalgia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (0% to 10%)<span class="lexi-table-link-container"> (<a aria-label="Conjunctivitis table link" class="lexi-table-link" data-table-id="lexi-content-conjunctivitis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-conjunctivitis')">table 1</a>)</span><span class="table-link" style="display:none;">Conjunctivitis</span>, eye pruritus (1%)<span class="lexi-table-link-container"> (<a aria-label="Eye Pruritus table link" class="lexi-table-link" data-table-id="lexi-content-eye-pruritus" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-eye-pruritus')">table 2</a>)</span><span class="table-link" style="display:none;">Eye Pruritus</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Conjunctivitis" frame="border" id="lexi-content-conjunctivitis" rules="all">
<caption style="text-align:center;">
<b>Dupilumab: Adverse Reaction: Conjunctivitis</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Dupilumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Dupilumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300 mg given every week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Eosinophilic esophagitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">122</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">117</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300 mg given every other week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Atopic dermatitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">529</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">517</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300 mg given every other week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Chronic rhinosinusitis with nasal polyposis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">440</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">282</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300 mg given every other week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Prurigo nodularis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">152</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">157</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Eye Pruritus" frame="border" id="lexi-content-eye-pruritus" rules="all">
<caption style="text-align:center;">
<b>Dupilumab: Adverse Reaction: Eye Pruritus</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Dupilumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Dupilumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300 mg given every other week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Atopic dermatitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">529</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">517</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (5%), oropharyngeal pain (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Thromboembolic complications (acute myocardial infarction, cerebrovascular accident)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, erythema nodosum, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction, serum sickness, serum sickness-like reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Dry eye syndrome, keratitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Aortic aneurysm (age ≥75 years) (Bridgewood 2022), edema, eosinophilic granulomatosis with polyangiitis (Persaud 2022), vasculitis (including hypersensitivity angiitis [Lommatzsch 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (Bridgewood 2022), acute generalized exanthematous pustulosis (Wu 2022), alopecia (areata) (Barbarin 2019), burning sensation of skin (Luo 2022), desquamation (Luo 2022), discoloration of sweat (infectious pseudochromhidrosis) (Kuo 2022), erythema of skin, facial erythema (Jo 2021), facial rash, papule of skin, pruritus (Nitro 2022), psoriasis (including nail psoriasis) (Beaziz 2021, Bridgewood 2022), skin pain, vitiligo (Bridgewood 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (Nitro 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hodgkin lymphoma (Nakazaki 2022), immune thrombocytopenia (Frey 2021), T-cell lymphoma (including cutaneous) (Ahatov 2022, Nakazaki 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Fritz 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Sarcoidosis (sarcoid-like granulomatosis and [neuro]sarcoid-like reaction) (Tsitos 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (Nitro 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (Nitro 2022), sleep disturbance (including nocturnal dyspnea) (Alroobaea 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis (seronegative) (Bridgewood 2022), arthropathy (enthesitis and enthesopathy) (Bridgewood 2022), back pain (Nitro 2022), joint swelling (Bridgewood 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharitis (Bohner 2021), blepharoconjunctivitis (Francuzik 2021), conjunctival scarring (Reddy 2022), corneal perforation (Phylactou 2022), corneal ulcer (Phylactou 2022), eye irritation (Bridgewood 2022), iridocyclitis (Bridgewood 2022), keratoconjunctivitis (Nguyen 2022), keratoconus (Bridgewood 2022), punctate keratitis (DiStaso 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Eosinophilic pneumonitis (Menzella 2019), epistaxis (Nitro 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Granuloma (annulare) (Phelps-Polirer 2022)</p></div>
<div class="block coi drugH1Div" id="F49748333"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known hypersensitivity to dupilumab or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F49955082"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Arthralgia: Arthralgia, including gait disturbances or decreased mobility associated with joint symptoms, has been reported, sometimes requiring hospitalization. May occur within days to months following initiation of therapy and has resolved with or without therapy discontinuation; report new-onset or worsening joint symptoms to health care provider.</p>
<p style="text-indent:-2em;margin-left:4em;">• Eosinophilia and vasculitis: In rare cases, patients may present with serious systemic eosinophilia, sometimes presenting with clinical features of eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis, a condition which is often treated with systemic corticosteroid therapy. Monitor for eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy, especially upon reduction of oral corticosteroids. A causal association between dupilumab and these underlying conditions has not been established.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Discontinuation or adjustment of asthma medications in patients treated with dupilumab should not be done without consulting health care provider.</p>
<p style="text-indent:-2em;margin-left:4em;">• Helminth infections: It is unknown if administration of dupilumab will influence a patient's response against parasitic infections; patients with known helminth infections were not studied. Adverse reactions of helminth infections were reported in pediatric patients 6 to 11 years of age who participated in the pediatric asthma development program. Therefore, patients with preexisting helminth infections should undergo treatment of the infection prior to initiation of dupilumab therapy. Patients who become infected during treatment and do not respond to anti-helminth therapy should discontinue dupilumab until the infection resolves.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concurrent drug therapy issues: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Corticosteroid therapy: Do not discontinue corticosteroids abruptly following initiation of dupilumab therapy. Reductions in corticosteroid dose should be gradual, if appropriate. Clinicians should note that a reduction in corticosteroid dose may be associated with withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Asthma: Therapy has not been shown to alleviate acute asthma exacerbations; do not use to treat acute bronchospasm or status asthmaticus.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Atopic dermatitis: Dupilumab may be used in combination with or without topical corticosteroids. Topical calcineurin inhibitors may be used but should be reserved for problem areas only (eg, face, neck intertriginous and genital areas).</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunogenicity: Dupilumab antibodies, including neutralizing antibodies, may develop; may be associated with lower serum dupilumab concentrations.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: Patients should be up to date with all immunizations before initiating therapy. Avoid the use of live vaccines in patients treated with dupilumab.</p></div>
<div class="block foc drugH1Div" id="F49955737"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dupixent: 300 mg/2 mL (2 mL); 200 mg/1.14 mL (1.14 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dupixent: 100 mg/0.67 mL (0.67 mL [DSC]) [latex free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dupixent: 300 mg/2 mL (2 mL); 200 mg/1.14 mL (1.14 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F49955735"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F50027560"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Dupixent Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200MG/1.14ML (per mL): $2,001.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/2 mL (per mL): $1,140.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Dupixent Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200MG/1.14ML (per mL): $2,001.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/2 mL (per mL): $1,140.96</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872261"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dupixent: 300 mg/2 mL (2 mL); 200 mg/1.14 mL (1.14 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dupixent: 300 mg/2 mL (2 mL); 200 mg/1.14 mL (1.14 mL) [contains polysorbate 80]</p></div>
<div class="block adm drugH1Div" id="F49955110"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>SUBQ:</b> Administer as a subcutaneous injection into the thigh or lower abdomen (avoiding areas within 2 inches of navel); caregiver may administer in upper arm. Rotate injection sites, including initial doses (administer 600 mg initial dose as two 300 mg injections at different sites; administer 400 mg initial dose as two 200 mg injections at different sites). Do not administer into skin that is tender, damaged, bruised, or scarred. Patients may self-administer injection after proper training. Allow solution to reach room temperature for 45 minutes (300 mg prefilled syringe or prefilled pen) or 30 minutes (200 mg prefilled syringe or prefilled pen; 100 mg prefilled syringe) prior to use; after removal from the refrigerator, must be used within 14 days or discarded. Do not heat prefilled pen in microwave, hot water, or direct sunlight; do not remove needle cap while allowing product to reach room temperature. Do not shake. Do not use if solution is discolored or contains particulate matter. Do not administer if window on prefilled pen is yellow (indicates pen has been used). Prefilled syringes and pens do not contain a preservative; discard unused portion. Refer to manufacturer's labeling for additional information.</p></div>
<div class="block admp drugH1Div" id="F52615020"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">SUBQ: Allow prefilled syringe/pen to reach room temperature for 45 minutes (300 mg prefilled syringe/pen) or 30 minutes (200 mg prefilled syringe/pen or 100 mg prefilled syringe) prior to use; do not remove needle cap while allowing product to reach room temperature; do not heat prefilled pen in microwave, hot water, or direct sunlight. Do not shake. Do not use if solution is discolored or contains particulate matter. Do not administer if window on prefilled pen is yellow (indicates pen has been used). Administer as a subcutaneous injection into the thigh or lower abdomen (avoiding areas within 2 inches of navel); caregiver may administer in patient's upper arm. Rotate injection sites, including initial doses (administer 600 mg initial dose as two 300 mg injections at different injection sites; administer 400 mg initial dose as two 200 mg injections at different injection sites). Do not administer into skin that is tender, damaged, bruised, or scarred. Prefilled syringes and pens do not contain a preservative; discard unused portion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Prefilled syringe may be used in ages ≥6 months; prefilled pen is only for use in ages ≥2 years. Patients ≥12 years of age may self-administer injection under adult supervision after proper training; doses in patients &lt;12 years of age should be administered by a properly trained caregiver.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose: </i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>For once-weekly dosing:</b> If a dose is missed, administer dose as soon as possible and start new weekly schedule from the date of last administered dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>For every-other-week dosing:</b> If a dose is missed, administer within 7 days from the missed dose and then resume the original schedule. If the missed dose is not administered within 7 days, wait until the next dose on the original schedule.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>For every-4-weeks dosing:</b> If a dose is missed, administer within 7 days from the missed dose and then resume the original schedule. If the missed dose is not administered within 7 days, a new schedule should be started based on the date next dose given.</p></div>
<div class="block use drugH1Div" id="F49748332"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, moderate to severe eosinophilic or oral glucocorticoid dependent: </b>Add-on maintenance treatment of moderate to severe asthma in adults and pediatric patients ≥6 years of age with an eosinophilic phenotype or with corticosteroid dependent asthma.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Not indicated for the relief of acute bronchospasm or status asthmaticus.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Atopic dermatitis:</b> Treatment of moderate to severe atopic dermatitis in adults and pediatric patients ≥6 months of age whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Eosinophilic esophagitis:</b> Treatment of adult and pediatric patients ≥12 years of age, weighing ≥40 kg, with eosinophilic esophagitis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prurigo nodularis:</b> Treatment of adult patients with prurigo nodularis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis (chronic) with nasal polyposis:</b> Add-on maintenance treatment in adults with inadequately controlled chronic rhinosinusitis with nasal polyposis.</p></div>
<div class="block off-label drugH1Div" id="F58343258"><span class="drugH1">Use: Off-Label: Adult</span><p>Chronic obstructive pulmonary disease, refractory (prevention of exacerbations)</p></div>
<div class="block cyt drugH1Div" id="F49766281"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F49766278"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Dupilumab may enhance the adverse/toxic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56830701"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Outcome data following use of dupilumab in patients planning a pregnancy are limited (Bosma 2021). In addition, data related to the use of monoclonal antibodies for the treatment of asthma during pregnancy are also limited. The long half-life of monoclonal antibodies should be considered when treating patients planning to become pregnant (Pfaller 2021). Use of an agent other than dupilumab may be preferred (ERS/TSANZ [Middleton 2020]).</p></div>
<div class="block pri drugH1Div" id="F49955080"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Dupilumab is a humanized monoclonal antibody (IgG<sub>4</sub>). Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following use of dupilumab in pregnant patients are limited primarily to case reports (Akhtar 2022; Costley 2022; Gracia-Darder 2021; Kage 2020; Kage 2021; Khamisy-Farah 2021; Lobo 2021; Mian 2020; Shakuntulla 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants, cesarean delivery, and the development of gestational diabetes). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. Maternal treatment improves pregnancy outcomes by reducing the risk of some adverse events (eg, preterm birth, gestational diabetes). Maternal asthma symptoms should be monitored monthly during pregnancy (ERS/TSANZ [Middleton 2020]; GINA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Data related to the use of monoclonal antibodies for the treatment of severe asthma during pregnancy are limited (GINA 2023). Use of monoclonal antibodies may be considered when conventional therapies are insufficient (ERS/TSANZ [Middleton 2020]). In general, monoclonal antibodies should not be initiated during pregnancy. The option to continue treatment in patients who become pregnant during therapy should be considered as part of a shared decision-making process (Dorscheid 2022; Pfaller 2021; Shakuntulla 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Therapies other than dupilumab are recommended for the treatment of atopic dermatitis in pregnant patients (Vestergaard 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to dupilumab is ongoing. Health care providers are encouraged to enroll exposed pregnant patients in the MotherToBaby Pregnancy Studies conducted by the Organization of Teratology Information Specialists (877-311-8972 or https://mothertobaby.org). Patients may also enroll themselves.</p></div>
<div class="block brc drugH1Div" id="F49955081"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if dupilumab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Dupilumab is a humanized monoclonal antibody (IgG<sub>4</sub>). Human IgG is present in breast milk; concentrations are dependent upon IgG subclass and postpartum age (Anderson 2021). Outcome data following use in breastfeeding patients is limited (Kage 2020; Kage 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Use of monoclonal antibodies for the treatment of asthma in lactating patients may be considered when conventional therapies are insufficient; use of an agent other than dupilumab may be preferred (ERS/TSANZ [Middleton 2020]).</p></div>
<div class="block mop drugH1Div" id="F49955113"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for signs/symptoms of arthralgia, hypersensitivity reactions, and ocular adverse effects (consider eye exam in patients with unresolved conjunctivitis); signs of infection; exacerbations, symptom control, and pulmonary function tests (eg, FEV<sub>1</sub>) in patients treated for asthma; consider rheumatological evaluation in patients with signs of arthralgia.</p></div>
<div class="block pha drugH1Div" id="F49955097"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Dupilumab is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by binding to the IL-4Rα subunit. Blocking IL-4Rα with dupilumab inhibits IL-4 and IL-13 cytokine-induced inflammatory responses, including the release of proinflammatory cytokines, chemokines, nitric oxide and IgE; however, the mechanism of dupilumab action in asthma has not been definitively established.</p></div>
<div class="block phk drugH1Div" id="F49955098"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~4.8 ± 1.3 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Monoclonal antibodies are primarily degraded into small peptides and amino acids by catabolism.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 61% to 64%.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~1 week.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance: The median time to non-detectable concentrations is 10 to 11 weeks (for 300 mg every 2 weeks), 13 weeks (for 300 mg weekly), and 9 weeks (for 200 mg every 2 weeks). In a population pharmacokinetic study, age did not affect clearance in ages ≥6 years; however, clearance is increased with age in infants ≥6 months to children ≤5 years.</p></div>
<div class="block phksp drugH1Div" id="F51154002"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Weight: Dupilumab trough concentrations were lower in subjects with higher body weight.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F51192306"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Dupixent</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31728936">
<a name="31728936"></a>Agnihotri G, Shi K, Lio PA. A Clinician's guide to the recognition and management of dupilumab-associated conjunctivitis. <i>Drugs R D</i>. 2019;19(4):311-318. doi:10.1007/s40268-019-00288-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/31728936/pubmed" id="31728936" target="_blank">31728936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35662852">
<a name="35662852"></a>Ahatov R, Good AJ, Joo M, Tipton S, Goodwin B, Kelly B. A rare case of aggressive cytotoxic T-cell lymphoma in a patient on dupilumab. <i>JAAD Case Rep</i>. 2022;24:112-114. doi:10.1016/j.jdcr.2022.04.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/35662852/pubmed" id="35662852" target="_blank">35662852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35115035">
<a name="35115035"></a>Akhtar NH, Khosravi-Hafshejani T, Akhtar D, Dhadwal G, Kanani A. The use of dupilumab in severe atopic dermatitis during pregnancy: a case report. <i>Allergy Asthma Clin Immunol</i>. 2022;18(1):9. doi:10.1186/s13223-022-00650-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/35115035/pubmed" id="35115035" target="_blank">35115035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30851191">
<a name="30851191"></a>Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. <i>Br J Dermatol</i>. 2019;181(3):459-473. doi:10.1111/bjd.17869<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/30851191/pubmed" id="30851191" target="_blank">30851191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35731078">
<a name="35731078"></a>Alroobaea R, Rubaiee S, Hanbazazah AS, et al. IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis. <i>Eur Rev Med Pharmacol Sci</i>. 2022;26(11):4074-4081. doi:10.26355/eurrev_202206_28977<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/35731078/pubmed" id="35731078" target="_blank">35731078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33956488">
<a name="33956488"></a>Anderson PO. Monoclonal antibodies during breastfeeding. <i>Breastfeed Med</i>. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/33956488/pubmed" id="33956488" target="_blank">33956488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33481203">
<a name="33481203"></a>Bansal A, Simpson EL, Paller AS, et al. Conjunctivitis in dupilumab clinical trials for adolescents with atopic dermatitis or asthma. <i>Am J Clin Dermatol</i>. 2021;22(1):101-115. doi:10.1007/s40257-020-00577-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/33481203/pubmed" id="33481203" target="_blank">33481203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31789276">
<a name="31789276"></a>Barbarin C, Hosteing S, Nosbaum A, Allouchery M, Celerier P. Early onset of alopecia areata after dupilumab introduction in a patient with atopic dermatitis. <i>Eur J Dermatol</i>. 2019;29(5):542-543. doi:10.1684/ejd.2019.3626<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/31789276/pubmed" id="31789276" target="_blank">31789276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30530389">
<a name="30530389"></a>Barroso-García B, Rial MJ, Molina A, Sastre J. Alopecia areata in severe atopic dermatitis treated with dupilumab. <i>J Investig Allergol Clin Immunol</i>. 2018;28(6):420-421. doi:10.18176/jiaci.0301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/30530389/pubmed" id="30530389" target="_blank">30530389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34175141">
<a name="34175141"></a>Beaziz J, Bouaziz JD, Jachiet M, Fite C, Lons-Danic D. Dupilumab-induced psoriasis and alopecia areata: case report and review of the literature. <i>Ann Dermatol Venereol</i>. 2021;148(3):198-201. doi:10.1016/j.annder.2021.02.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/34175141/pubmed" id="34175141" target="_blank">34175141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37272521">
<a name="37272521"></a>Bhatt SP, Rabe KF, Hanania NA, et al; BOREAS Investigators. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. <i>N Engl J Med</i>. 2023. doi:10.1056/NEJMoa2303951<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/37272521/pubmed" id="37272521" target="_blank">37272521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32826648">
<a name="32826648"></a>Bohner A, Topham C, Strunck J, et al. Dupilumab-associated ocular surface disease: clinical characteristics, treatment, and follow-up. <i>Cornea</i>. 2021;40(5):584-589. doi:10.1097/ICO.0000000000002461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/32826648/pubmed" id="32826648" target="_blank">32826648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33969522">
<a name="33969522"></a>Bosma AL, Gerbens LAA, Middelkamp-Hup MA, Spuls PI. Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series. <i>Clin Exp Dermatol</i>. 2021;46(6):1089-1092. doi:10.1111/ced.14725<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/33969522/pubmed" id="33969522" target="_blank">33969522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35395222">
<a name="35395222"></a>Bridgewood C, Wittmann M, Macleod T, et al. T Helper 2 IL-4/IL-13 dual blockade with dupilumab is linked to some emergent T Helper 17‒type diseases, including seronegative arthritis and enthesitis/enthesopathy, but not to humoral autoimmune diseases. <i>J Invest Dermatol</i>. 2022;142(10):2660-2667. doi:10.1016/j.jid.2022.03.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/35395222/pubmed" id="35395222" target="_blank">35395222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol</i>. 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32956738">
<a name="32956738"></a>Cheng J, Jiang L, Morrow NC, et al. Recognition of atopic keratoconjunctivitis during treatment with dupilumab for atopic dermatitis. <i>J Am Acad Dermatol</i>. 2021;85(1):265-267. doi:10.1016/j.jaad.2020.09.046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/32956738/pubmed" id="32956738" target="_blank">32956738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34856015">
<a name="34856015"></a>Costley M, Murphy B. Severe atopic dermatitis treated successfully with dupilumab throughout pregnancy. <i>Clin Exp Dermatol</i>. 2022;47(5):960-961. doi:10.1111/ced.15049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/34856015/pubmed" id="34856015" target="_blank">34856015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32665517">
<a name="32665517"></a>DeGrazia TM, Raji K, Alshamekh S, Chisolm S. Psoriatic plaques after initiation of dupilumab therapy. <i>Dermatitis</i>. 2020;31(4):e36-e37. doi:10.1097/DER.0000000000000570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/32665517/pubmed" id="32665517" target="_blank">32665517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35128157">
<a name="35128157"></a>Di Staso F, Lambiase A, Silvio Di Staso, Gattazzo I, Ciancaglini M, Scuderi G. Topical treatment of dupilumab-associated refractory conjunctivitis and keratitis. <i>Am J Ophthalmol Case Rep</i>. 2022;25:101309. doi:10.1016/j.ajoc.2022.101309<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/35128157/pubmed" id="35128157" target="_blank">35128157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36124286">
<a name="36124286"></a>Dorscheid DR, Lee JK, Ramesh W, Greenwald M, Del Carpio J. Guidance for administering biologics for severe asthma and allergic conditions. <i>Can Respir J.</i> 2022;2022:9355606. doi:10.1155/2022/9355606<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/36124286/pubmed" id="36124286" target="_blank">36124286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dupixent.1">
<a name="Dupixent.1"></a>Dupixent (dupilumab) [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34114910">
<a name="34114910"></a>Francuzik W, Alexiou A, Worm M. Safety of dupilumab in patients with atopic dermatitis: expert opinion. <i>Expert Opin Drug Saf</i>. 2021;20(9):997-1004. doi:10.1080/14740338.2021.1939673<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/34114910/pubmed" id="34114910" target="_blank">34114910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33349889">
<a name="33349889"></a>Frey S, Kendziora B, Holch JW, Lindner L, French LE, Wollenberg A. Immune thrombocytopenic purpura in a patient with atopic dermatitis treated with dupilumab. <i>Acta Derm Venereol</i>. 2021;101(3):adv00409. doi:10.2340/00015555-3734<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/33349889/pubmed" id="33349889" target="_blank">33349889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33099796">
<a name="33099796"></a>Fritz AL, Lacy FA, Morrell DS. Angioedema: a potential complication of dupilumab in atopic dermatitis. <i>Pediatr Dermatol</i>. 2021;38(1):237-238. doi:10.1111/pde.14434<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/33099796/pubmed" id="33099796" target="_blank">33099796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.1">
<a name="GINA.1"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/2023-gina-main-report/. Updated 2023. Accessed August 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34850510">
<a name="34850510"></a>Gracia-Darder I, Pons De Ves J, Reyero Cortina M, Martín-Santiago A. Patient with atopic dermatitis, hyper IgE syndrome and ulcerative colitis, treated successfully with dupilumab during pregnancy. <i>Dermatol Ther</i>. 2021:e15237. doi:10.1111/dth.15237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/34850510/pubmed" id="34850510" target="_blank">34850510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34495603">
<a name="34495603"></a>Guex-Crosier Y, Di-Lucca J, Häusermann P, et al. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients. <i>Swiss Med Wkly</i>. 2021;151:w30020. doi:10.4414/SMW.2021.w30020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/34495603/pubmed" id="34495603" target="_blank">34495603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32822798">
<a name="32822798"></a>Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. <i>J Am Acad Dermatol</i>. 2021;84(1):139-147. doi:10.1016/j.jaad.2020.08.051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/32822798/pubmed" id="32822798" target="_blank">32822798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31994421">
<a name="31994421"></a>Jackson K, Bahna SL. Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases. <i>Expert Rev Clin Immunol</i>. 2020;16(3):311-319. doi:10.1080/1744666X.2020.1724089<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/31994421/pubmed" id="31994421" target="_blank">31994421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33428978">
<a name="33428978"></a>Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: a systematic review. <i>J Am Acad Dermatol</i>. 2021;84(5):1339-1347. doi:10.1016/j.jaad.2021.01.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/33428978/pubmed" id="33428978" target="_blank">33428978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30372706">
<a name="30372706"></a>Jorge E, Clark J. Dupilumab for off-label treatment of moderate to severe childhood atopic dermatitis. <i>Cutis</i>. 2018;102(3):201-204.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/30372706/pubmed" id="30372706" target="_blank">30372706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31990389">
<a name="31990389"></a>Kage P, Simon JC, Treudler R. A case of atopic eczema treated safely with dupilumab during pregnancy and lactation. <i>J Eur Acad Dermatol Venereol</i>. 2020;34(6):e256-e257. doi:10.1111/jdv.16235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/31990389/pubmed" id="31990389" target="_blank">31990389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34342905">
<a name="34342905"></a>Kage P, Simon JC, Treudler R. Case of atopic eczema treated with dupilumab throughout conception, pregnancy, and lactation. <i>J Dermatol</i>. 2021;48(10):E484-E485. doi:10.1111/1346-8138.16033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/34342905/pubmed" id="34342905" target="_blank">34342905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34533820">
<a name="34533820"></a>Khamisy-Farah R, Damiani G, Kong JD, Wu JH, Bragazzi NL. Safety profile of dupilumab during pregnancy: a data mining and disproportionality analysis of over 37,000 reports from the WHO individual case safety reporting database (VigiBase™). <i>Eur Rev Med Pharmacol Sci</i>. 2021;25(17):5448-5451. doi:10.26355/eurrev_202109_26652<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/34533820/pubmed" id="34533820" target="_blank">34533820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35712045">
<a name="35712045"></a>Kuo ME, Briones NF, Helfrich YR. Infectious pseudochromhidrosis in the setting of dupilumab use. <i>JAAD Case Rep</i>. 2022;25:27-29. doi:10.1016/j.jdcr.2022.05.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/35712045/pubmed" id="35712045" target="_blank">35712045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34177514">
<a name="34177514"></a>Lobo Y, Lee RC, Spelman L. Atopic dermatitis treated safely with dupilumab during pregnancy: a case report and review of the literature. <i>Case Rep Dermatol</i>. 2021;13(2):248-256. doi:10.1159/000515246<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/34177514/pubmed" id="34177514" target="_blank">34177514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34047387">
<a name="34047387"></a>Lommatzsch M, Stoll P, Winkler J, et al. Eosinophilic pleural effusion and stroke with cutaneous vasculitis: Two cases of dupilumab-induced hypereosinophilia. <i>Allergy</i>. 2021;76(9):2920-2923. doi:10.1111/all.14964<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/34047387/pubmed" id="34047387" target="_blank">34047387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36000004">
<a name="36000004"></a>Luo N, Wang Q, Lei M, Li Z, Li T, Hao P. Burning and scaling probably associated with dupilumab therapy: a case report. <i>Clin Cosmet Investig Dermatol</i>. 2022;15:1659-1662. doi:10.2147/CCID.S373997<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/36000004/pubmed" id="36000004" target="_blank">36000004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32995444">
<a name="32995444"></a>Mian M, Dunlap R, Simpson E. Dupilumab for the treatment of severe atopic dermatitis in a pregnant patient: a case report. <i>JAAD Case Rep</i>. 2020;6(10):1051-1052. doi:10.1016/j.jdcr.2020.08.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/32995444/pubmed" id="32995444" target="_blank">32995444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32178985">
<a name="32178985"></a>Matsuda T, Yamada H, Hida N, et al. An asthmatic case of psoriasiform eruption caused by administration of dupilumab. <i>Allergol Int</i>. 2020;69(3):478-479. doi:10.1016/j.alit.2020.02.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/32178985/pubmed" id="32178985" target="_blank">32178985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31371974">
<a name="31371974"></a>Menzella F, Montanari G, Patricelli G, et al. A case of chronic eosinophilic pneumonia in a patient treated with dupilumab. <i>Ther Clin Risk Manag</i>. 2019;15:869-875. doi:10.2147/TCRM.S207402<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/31371974/pubmed" id="31371974" target="_blank">31371974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699837">
<a name="31699837"></a>Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases.<i> Eur Respir J.</i> 2020;55(2):1901208. doi:10.1183/13993003.01208-2019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/31699837/pubmed" id="31699837" target="_blank">31699837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34917722">
<a name="34917722"></a>Mustin DE, Cole EF, Blalock TW, Kalangara ME, Stoff BK, Feldman RJ. Dupilumab-induced erythema nodosum. <i>JAAD Case Rep</i>. 2021;19:41-43. doi:10.1016/j.jdcr.2021.11.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/34917722/pubmed" id="34917722" target="_blank">34917722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32622143">
<a name="32622143"></a>Muzumdar S, Zubkov M, Waldman R, DeWane ME, Wu R, Grant-Kels JM. Characterizing dupilumab facial redness in children and adolescents: a single-institution retrospective chart review. <i>J Am Acad Dermatol</i>. 2020;83(5):1520-1521. doi:10.1016/j.jaad.2020.06.1003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/32622143/pubmed" id="32622143" target="_blank">32622143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31554632">
<a name="31554632"></a>Nahum Y, Mimouni M, Livny E, Bahar I, Hodak E, Leshem YA. Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. <i>Br J Ophthalmol</i>. 2020;104(6):776-779. doi:10.1136/bjophthalmol-2019-315010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/31554632/pubmed" id="31554632" target="_blank">31554632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35355217">
<a name="35355217"></a>Nakazaki K, Yoshida M, Masamoto Y, et al. Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis. <i>Int J Hematol</i>. 2022;116(3):446-452. doi:10.1007/s12185-022-03330-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/35355217/pubmed" id="35355217" target="_blank">35355217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36160495">
<a name="36160495"></a>Nguyen MT, Tsukikawa M, Lomazow W, Lee M. Irreversible bilateral cicatricial keratoconjunctivitis after dupilumab therapy. <i>Case Rep Ophthalmol</i>. 2022;13(2):638-642. doi:10.1159/000525738<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/36160495/pubmed" id="36160495" target="_blank">36160495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36160495">
<a name="36160495"></a>Nitro L, Bulfamante AM, Rosso C, et al. Adverse effects of dupilumab in chronic rhinosinusitis with nasal polyps. Case report and narrative review. <i>Acta Otorhinolaryngol Ital</i>. 2022;42(3):199-204. doi:10.14639/0392-100X-N1911<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/36160495/pubmed" id="36160495" target="_blank">36160495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies.<i> Clin Dev Immunol.</i> 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies.<i> Birth Defects Res B Dev Reprod Toxicol.</i> 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36072184">
<a name="36072184"></a>Persaud P, Karmali R, Sankar P, Majid M. Dupilumab-associated eosinophilic granulomatosis with polyangiitis. <i>Cureus</i>. 2022;14(8):e27670. doi:10.7759/cureus.27670<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/36072184/pubmed" id="36072184" target="_blank">36072184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32189356">
<a name="32189356"></a>Pfaller B, José Yepes-Nuñez J, Agache I, et al. Biologicals in atopic disease in pregnancy: an EAACI position paper. <i>Allergy</i>. 2021;76(1):71-89. doi:10.1111/all.14282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/32189356/pubmed" id="32189356" target="_blank">32189356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36051735">
<a name="36051735"></a>Phelps-Polirer K, Alkhatib BL, Davis C. Generalized granuloma annulare associated with dupilumab therapy. <i>Cureus</i>. 2022;14(7):e27439. doi:10.7759/cureus.27439<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/36051735/pubmed" id="36051735" target="_blank">36051735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34928552">
<a name="34928552"></a>Phylactou M, Jabbour S, Ahmad S, Vasquez-Perez A. Corneal perforation in patients under treatment with dupilumab for atopic dermatitis. <i>Cornea</i>. 2022;41(8):981-985. doi:10.1097/ICO.0000000000002854<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/34928552/pubmed" id="34928552" target="_blank">34928552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35479518">
<a name="35479518"></a>Reddy AK, Hauswirth SG, Gregory DG, Liao SD, Palestine AG. Dupilumab-associated cicatrizing ocular disease. <i>Am J Ophthalmol Case Rep</i>. 2022;26:101528. doi:10.1016/j.ajoc.2022.101528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/35479518/pubmed" id="35479518" target="_blank">35479518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34310097">
<a name="34310097"></a>Russo F, Provvidenziale L, Bruzziches F, et al. Psoriasis-like eruption triggered by dupilumab therapy. <i>Dermatitis</i>. 2021;32(6):e147-e148. doi:10.1097/DER.0000000000000740<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/34310097/pubmed" id="34310097" target="_blank">34310097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33038471">
<a name="33038471"></a>Schneeweiss MC, Kim SC, Wyss R, Schneeweiss S, Merola JF. Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: a propensity score-matched cohort study. <i>J Am Acad Dermatol</i>. 2021;84(2):300-311. doi:10.1016/j.jaad.2020.09.084<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/33038471/pubmed" id="33038471" target="_blank">33038471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35987486">
<a name="35987486"></a>Shakuntulla F, Chiarella SE. Safety of biologics for atopic diseases during pregnancy. <i>J Allergy Clin Immunol Pract.</i> 2022;10(12):3149-3155. doi:10.1016/j.jaip.2022.08.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/35987486/pubmed" id="35987486" target="_blank">35987486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27690741">
<a name="27690741"></a>Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. <i>N Engl J Med</i>. 2016;375(24):2335-2348.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/27690741/pubmed" id="27690741" target="_blank">27690741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30167653">
<a name="30167653"></a>Treister AD, Kraff-Cooper C, Lio PA. Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. <i>JAMA Dermatol</i>. 2018;154(10):1208-1211. doi:10.1001/jamadermatol.2018.269<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/30167653/pubmed" id="30167653" target="_blank">30167653</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30338546">
<a name="30338546"></a>Treister AD, Lio PA. Long-term off-label dupilumab in pediatric atopic dermatitis: a case series. <i>Pediatr Dermatol</i>. 2019;36(1):85-88.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/30338546/pubmed" id="30338546" target="_blank">30338546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32594596">
<a name="32594596"></a>Treudler R, Delaroque N, Puder M, Simon JC, Szardenings M. Dupilumab-induced serum sickness-like reaction: an unusual adverse effect in a patient with atopic eczema. <i>J Eur Acad Dermatol Venereol</i>. 2021;35(1):e30-e32. doi:10.1111/jdv.16782<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/32594596/pubmed" id="32594596" target="_blank">32594596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35795795">
<a name="35795795"></a>Tsitos S, Niederauer LC, Albert I Gracenea P, Mueller J, Straube A, Von Baumgarten L. Case report: drug-induced (neuro) sarcoidosis-like lesion under IL4 receptor blockade with dupilumab. <i>Front Neurol</i>. 2022;13:881144. doi:10.3389/fneur.2022.881144<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/35795795/pubmed" id="35795795" target="_blank">35795795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31231864">
<a name="31231864"></a>Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. <i>J Eur Acad Dermatol Venereol</i>. 2019;33(9):1644-1659. doi:10.1111/jdv.15709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/31231864/pubmed" id="31231864" target="_blank">31231864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31228530">
<a name="31228530"></a>Waldman RA, DeWane ME, Sloan B, Grant-Kels JM. Characterizing dupilumab facial redness: a multi-institution retrospective medical record review. <i>J Am Acad Dermatol</i>. 2020;82(1):230-232. doi:10.1016/j.jaad.2019.06.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/31228530/pubmed" id="31228530" target="_blank">31228530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33725800">
<a name="33725800"></a>Wang Y, Jorizzo JL. Retrospective analysis of adverse events with dupilumab reported to the United States Food and Drug Administration. <i>J Am Acad Dermatol</i>. 2021;84(4):1010-1014. doi:10.1016/j.jaad.2020.11.042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/33725800/pubmed" id="33725800" target="_blank">33725800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30275849">
<a name="30275849"></a>Warrington R, Silviu-Dan F, Wong T. Drug allergy. <i>Allergy Asthma Clin Immunol</i>. 2018;14(suppl 2):60. doi:10.1186/s13223-018-0289-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/30275849/pubmed" id="30275849" target="_blank">30275849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35814891">
<a name="35814891"></a>Wilson MM, Roberts PK, Daniell M. Dupilumab-associated ulcerative keratitis. <i>Int J Ophthalmol</i>. 2022;15(6):1020-1022. doi:10.18240/ijo.2022.06.23<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/35814891/pubmed" id="35814891" target="_blank">35814891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35670324">
<a name="35670324"></a>Wu L, Ali K, Qiu Y, Li M, Da J. Dupilumab-induced acute generalized exanthematous pustulosis in a 17-year-old female Chinese patient with atopic dermatitis. <i>Acta Derm Venereol</i>. 2022;102:adv00743. doi:10.2340/actadv.v102.1079<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dupilumab-drug-information/abstract-text/35670324/pubmed" id="35670324" target="_blank">35670324</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 112484 Version 194.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
